Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis.

Su, Wanting; Miao, He; Guo, Zhaotian; Chen, Qianhui; Huang, Tao; Ding, Renyu

Su, Wanting; Miao, He; Guo, Zhaotian; Chen, Qianhui; Huang, Tao; Ding, Renyu.

Afiliación

Su W; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Miao H; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Guo Z; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Chen Q; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Huang T; Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China.
Ding R; Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education, Beijing, China.

Front Pharmacol ; 13: 989903, 2022.

Article en En | MEDLINE | ID: mdl-36278186

Palabras clave

COVID-19; antiplatelet drug; aspirin; meta-analysis; mortality

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google